SCHEMBL718651

SCHEMBL718651

Cc1c(C(=O)C(C)C)oc2ccc(OC3CCSCC3)cc12

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.44
RAB9A P51151 7/20 0.44
KDM4E B2RXH2 9/20 0.43
ALDH1A1 P00352 7/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
HPGD P15428 3/20 0.41
POLB P06746 2/20 0.40
ACSL3 O95573 1/20 0.40
ACSL1 P33121 1/20 0.40
ACSL6 Q9UKU0 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL719770 0.79 ACSL1 (0.36) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL718963 0.77 KDM4E (0.53) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL718514 0.73 MCL1 (0.43) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL720808 0.72 KDM4E (0.55) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL720361 0.71 POLB (0.49) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL720265 0.70 CASP3 (0.60) NPC1RAB9AKDM4EL3MBTL1MEN1
SCHEMBL716722 0.70 RAB9A (0.51) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL23665874 0.70 MCL1 (0.70) RAB9AKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL718725 0.70 RAB9A (0.54) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL719276 0.70 KCNH2 (0.63) NPC1RAB9AKDM4EL3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885RAB9A 2454/4885KDM4E 1907/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885RAB9A 2454/4885KDM4E 1907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.